Ozempic maker Novo Nordisk’s shares plunge 18% on bleak 2026 forecast

February 4, 2026
Uncategorized

Novo Nordisk shares plunged 18% after pre-releasing a weak 2026 outlook, citing US pricing pressure on Wegovy. CEO Mike Doustdar warned of near-term headwinds despite pill launch success.

Ozempic maker Novo Nordisk’s shares plunge 18% on bleak 2026 forecast

Leave a ReplyCancel Reply

Kalpataru Projects Q3 Results: Profit up as record revenue, strong order book sustain growth

Jubilant Ingrevia Q3 net profit falls 32% on flat revenue; dividend ₹2.50 declared

Gallantt Ispat Q3 Results: Profit, EBITDA declines YoY; margin contracts

HAL downplays AMCA exclusion reports even as Bharat Forge, Tata, L&T make the shortlist

Redington Q3 net profit up 3%, revenue rises 16% on strong solutions-led growth